A Critical Assessment of the Therapeutic Potential of Resveratrol Supplements for Treating Mitochondrial Disorders
Abstract
:1. Introduction
2. The Stimulatory Effect of Resveratrol on Mitogenesis and Mitochondrial Interconnections
3. The Regulatory Effect of Resveratrol on OXPHOS
4. The Protective Effect of Resveratrol on Oxidative Cell Stress
5. The Anti-Apoptotic Effect of Resveratrol
6. Resveratrol Supplementation as a Treatment for Mitochondrial Disorders
7. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Cannino, G.; Di Liegro, C.M.; Rinaldi, A.M. Nuclear-mitochondrial interaction. Mitochondrion 2007, 7, 359–366. [Google Scholar] [CrossRef] [PubMed]
- Van den Heuvel, L.; Smeitink, J. The oxidative phosphorylation (OXPHOS) system: Nuclear genes and human genetic diseases. Bioessays 2001, 23, 518–525. [Google Scholar] [CrossRef] [PubMed]
- Zeviani, M.; Di Donato, S. Mitochondrial disorders. Brain 2004, 127, 2153–2172. [Google Scholar] [CrossRef] [PubMed]
- Morris, A.A.M.; Leonard, J.V.; Brown, G.K.; Bidouki, S.K.; Bindoff, L.A.; Turnbull, D.M.; Woodward, C.E.; Harding, A.E.; Lake, B.D.; Harding, B.N.; et al. Deficiency of respiratory chain complex I is a common cause of leigh disease. Ann. Neurol. 1996, 40, 25–30. [Google Scholar] [CrossRef] [PubMed]
- Suomalainen, A.; Isohanni, P. Mitochondrial DNA depletion syndromes–many genes, common mechanisms. Neuromuscul. Disord. 2010, 20, 429–437. [Google Scholar] [CrossRef] [PubMed]
- Tuppen, H.A.L.; Blakely, E.L.; Turnbull, D.M.; Taylor, R.W. Mitochondrial DNA mutations and human disease. Biochim. Biophys. Acta 2010, 1797, 113–128. [Google Scholar] [CrossRef] [PubMed]
- Pfeffer, G.; Majamaa, K.; Turnbull, D.M.; Thorburn, D.; Chinnery, P.F. Treatment for mitochondrial disorders. Cochrane Database Syst. Rev. 2012, 4, e4426. [Google Scholar]
- Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Spiegelman, B.M.; Puigserver, P. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 2005, 434, 113–118. [Google Scholar] [CrossRef] [PubMed]
- Scarpulla, R.C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta 2011, 1813, 1269–1278. [Google Scholar] [CrossRef] [PubMed]
- Wenz, T.; Diaz, F.; Spiegelman, B.M.; Moraes, C.T. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively imporves a mitochondrial myopathy genotype. Cell Metab. 2008, 8, 249–256. [Google Scholar] [CrossRef] [PubMed]
- Rodgers, J.T.; Lerin, C.; Gerhart-Hines, Z.; Puigserver, P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 2008, 582, 46–53. [Google Scholar] [CrossRef] [PubMed]
- Gerhart-Hines, Z.; Rodgers, J.T.; Bare, O.; Lerin, C.; Kim, S.H.; Mostoslavsky, R. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007, 26, 1913–1923. [Google Scholar] [CrossRef] [PubMed]
- Youle, R.J.; van der Bliek, A.M. Mitochondrial fission, fusion, and stress. Science 2012, 337, 1062–1065. [Google Scholar] [CrossRef] [PubMed]
- Schieke, S.M.; Ma, M.; Cao, L.; McCoy, J.P.; Liu, C.; Hensel, N.F.; Barrett, A.J.; Boehm, M.; Finkel, T. Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J. Biol. Chem. 2008, 283, 28506–28512. [Google Scholar] [CrossRef] [PubMed]
- Cassidy-Stone, A.; Chipuk, J.E.; Ingerman, E.; Song, C.; Yoo, C.; Kuwana, T.; Kurth, M.J.; Shaw, J.T.; Hinshaw, J.E.; Green, D.R.; et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell 2008, 14, 193–204. [Google Scholar] [CrossRef] [PubMed]
- Giordano, C.; Iommarini, L.; Giordano, L.; Maresca, A.; Pisano, A.; Valentino, M.L.; Caporali, L.; Liguori, R.; Deceglie, S.; Roberti, M.; et al. Efficient mitochondrial biogenesis drives incomplete penetrance in Leber’s hereditary optic neuropathy. Brain 2014, 137, 335–353. [Google Scholar] [CrossRef] [PubMed]
- Taivassalo, T.; Haller, R.G. Implications of exercise training in mtDNA defects-use it or lose it? Biochim. Biophys. Acta 2004, 1659, 221–231. [Google Scholar] [CrossRef] [PubMed]
- Srivastava, S.; Diaz, F.; Iommarini, L.; Aure, K.; Lombes, A.; Moraes, C.T. PGC-1α induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum. Mol. Genet. 2009, 18, 1805–1812. [Google Scholar] [CrossRef] [PubMed]
- Park, S.J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A.L.; et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodieterases. Cell 2012, 148, 421–433. [Google Scholar] [CrossRef] [PubMed]
- Price, N.L.; Gomes, A.P.; Ling, A.J.Y.; Duarte, F.V.; Martin-Montalvo, A.; North, B.J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J.S.; et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15, 675–690. [Google Scholar] [CrossRef] [PubMed]
- Csiszar, A.; Labinskyy, N.; Pinto, J.T.; Ballabh, P.; Zhang, H.; Losonczy, G.; Pearson, K.; de Cabo, R.; Pacher, P.; Zhang, C.; et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297, H13–H20. [Google Scholar] [CrossRef] [PubMed]
- Robb, E.L.; Moradi, F.; Maddalena, L.A.; Valente, A.J.F.; Fonseca, J.; Stuart, J.A. Resveratrol stimulates mitochondrial fusion by a mechanism requiring mitofusin-2. Biochem. Biophys. Res. Commun. 2017, 485, 249–254. [Google Scholar] [CrossRef] [PubMed]
- Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127, 1109–1122. [Google Scholar] [CrossRef] [PubMed]
- Viscomi, C.; Bottani, E.; Civiletto, G.; Cerutti, R.; Moggio, M.; Fagiolari, G.; Schon, E.A.; Lamperti, C.; Zeviani, M. In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell Metab. 2011, 14, 80–90. [Google Scholar] [CrossRef] [PubMed]
- Lopes Costa, A.; Le Bachelier, C.; Mathieu, L.; Rotig, A.; Boneh, A.; De Lonlay, P.; Tarnopolsky, M.A.; Thornburn, D.R.; Bastin, J.; Djouadi, F. Benefical effects of resveratrol on respiratory chain defects in patients’ fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling. Hum. Mol. Genet. 2014, 23, 2106–2119. [Google Scholar] [CrossRef] [PubMed]
- Desquiret-Dumas, V.; Gueguen, N.; Leman, G.; Baron, S.; Nivet-Antoine, V.; Chupin, S.; Chevrollier, A.; Vessières, E.; Ayer, A.; Ferré, M.; et al. Resveratrol Induces a Mitochondrial Complex I-Dependent Increase in NADH Oxidation Responsible for Sirtuin Activation in Liver Cells. J. Biol. Chem. 2013, 288, 36662–36675. [Google Scholar] [CrossRef] [PubMed]
- Gueguen, N.; Desquiret-Dumas, V.; Leman, G.; Chupin, S.; Baron, S.; Nivet-Antoine, V.; Vessières, E.; Ayer, A.; Henrion, D.; Lenaers, G.; et al. Resveratrol Directly Binds to Mitochondrial Complex I and Increases Oxidative Stress in Brain Mitochondria of Aged Mice. PLoS ONE 2015, 10, e0144290. [Google Scholar] [CrossRef] [PubMed]
- Zini, R.; Morin, C.; Bertelli, A.; Bertelli, A.A.; Tillement, J.P. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp. Clin. Res. 1999, 25, 87–97. [Google Scholar] [PubMed]
- Kipp, J.L.; Ramirez, V.D. Effect of estradiol, diethylstilbestrol, and resveratrol on F0F1-ATPase activity from mitochondrial preparations of rat heart, liver, and brain. Endocrine 2001, 15, 165–175. [Google Scholar] [CrossRef]
- Zheng, J.; Ramirez, V.D. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol. 2000, 130, 1115–1123. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Zhang, J.; Lin, Y.; Lei, Q.; Guan, K.L.; Zhao, S.; Xiang, Y. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. 2011, 12, 534–541. [Google Scholar] [CrossRef] [PubMed]
- Pearson, K.J.; Baur, J.A.; Lewis, K.N.; Peshkin, L.; Price, N.L.; Labinskyy, N.; Swindell, W.R.; Kamara, D.; Minor, R.K.; Perez, E.; et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8, 157–168. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ungvari, Z.; Bagi, Z.; Feher, A.; Recchia, F.A.; Sonntag, W.E.; Pearson, K.; de Cabo, R.; Csiszar, A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010, 299, H18–H24. [Google Scholar] [CrossRef] [PubMed]
- Ham, P.B.; Raju, R. Mitochondrial Function in Hypoxic Ischemic Injury and Influence of Aging. 2017. Available online: http://www.sciencedirect.com/science/article/pii/S0301008215300654 (accessed on 14 September 2017). [CrossRef]
- Fu, B.; Zhao, J.; Peng, W.; Wu, H.; Zhang, Y. Resveratrol rescues cadmium-induced mitochondrial injury by enhancing transcriptional regulation of PGC-1a and SOD2 via the Sirt3/FoxO3a pathway in TCMK-1 cells. Biochem. Biophys. Res. Commun. 2017, 486, 198–204. [Google Scholar] [CrossRef] [PubMed]
- Bause, A.S.; Haigis, M.C. SIRT3 regulation of mitochondrial oxidative stress. Exp. Gerontol. 2013, 48, 634–639. [Google Scholar] [CrossRef] [PubMed]
- Mitra, S.; Bhattacharyya, S.; Ray, S.; Saha, R.; Ghosh, P.; Rauth, S.; Mandal, S.; Banerjee, S.; Murmu, N. Resveratrol alleviates cadmium-ionduced damage and overexpression of epidermal growth factor receptor and its downstream signaling proteins in the reproductive system of male Swiss albino mice. J. Environ. Pathol. Toxicol. Oncol. 2016, 35, 73–90. [Google Scholar] [CrossRef] [PubMed]
- Adhihetty, P.J.; Hood, D.A. Mechanisms of Apoptosis in Skeletal Muscle. Basic Appl. Myol. 2003, 13, 171–179. [Google Scholar]
- Suen, D.F.; Norris, K.L.; Youle, R.J. Mitochondrial dynamics and apoptosis. Genes Dev. 2008, 22, 1577–1590. [Google Scholar] [CrossRef] [PubMed]
- Mirabella, M.; Di Giovanni, S.; Silvestri, G.; Tonali, P.; Servidei, S. Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain 2000, 123, 93–104. [Google Scholar] [CrossRef] [PubMed]
- Roqanian, S.; Meratan, A.A.; Ahmadian, S.; Shafizadeh, M.; Ghasemi, A.; Karami, L. Polyphenols protect mitochondrial membrane against permeabilization induced by HEWL oligomers: Possible mechanism of action. Int. J. Biol. Macromol. 2017, 103, 709–720. [Google Scholar] [CrossRef] [PubMed]
- Mizuguchi, Y.; Hatakeyama, H.; Sueoka, K.; Tanaka, K.; Goto, Y.I. Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming. Mitochondrion 2017, 34, 43–48. [Google Scholar] [CrossRef] [PubMed]
- Mathieu, L.; Lopes Costa, A.; Le Bachelier, C.; Slama, A.; Lebre, A.S.; Taylor, R.W.; Bastin, J.; Djouadi, F. Resveratrol attenuates oxidative stress in mitochondrial complex I deficiency: Involvement of SIRT3. Free Radic. Biol. Med. 2016, 96, 190–198. [Google Scholar] [CrossRef] [PubMed]
- Douiev, L.; Soiferman, D.; Alban, C.; Saada, A. The effects of ascorbate, N-acetylcysteine, and resveratrol on fibroblasts from patients with mitochondrial disorders. J. Clin. Med. 2017, 6. [Google Scholar] [CrossRef] [PubMed]
- De Paepe, B.; Vandemeulebroecke, K.; Smet, J.; Vanlander, A.; Seneca, S.; Lissens, W.; Van Hove, J.L.K.; Deschepper, E.; Briones, P.; Van Coster, R. Effect of resveratrol on cultured skin fibroblasts from patients with oxidative phosphorylation defects. Phytother. Res. 2014, 28, 312–316. [Google Scholar] [CrossRef] [PubMed]
- Robinson, B.H. Lactic acidemia and mitochondrial disease. Mol. Genet. Metab. 2006, 89, 3–13. [Google Scholar] [CrossRef] [PubMed]
- Always, S.E.; McCrory, J.L.; Kearcher, K.; Vickers, A.; Frear, B.; Gilleland, D.L.; Bonner, D.E.; Thomas, J.M.; Donley, D.A.; Lively, M.W.; et al. Resveratrol Enhances Exercise-induced Cellular and Functional Adaptations of Skeletal Muscle in Older Men and Women. 2017. Available online: https://academic.oup.com/biomedgerontology/article-abstract/3824856/Resveratrol-enhances-exercise-induced-cellular-and (accessed on 14 September 2017). [CrossRef]
Mutation | Deficiency | Regimen | Outcome | Reference |
---|---|---|---|---|
m.3243A>G TL1 | not reported | 0.01 μM 24 h | basal OCR and ATP production significantly ↑ | [42] |
m.8344A>G TK | not reported | 0.01 μM 24 h | basal OCR and ATP production significantly ↑ | [42] |
m.8993T>G ATP6 | not reported | 0.01 μM 24 h | basal OCR and ATP production significantly ↑ | [42] |
c.611A>G NDUFV1 | complex I | 75 μM 48 h 72 h | OCR and complex I activity significantly ↑ | [25] |
c.640G>A NDUFV1 | complex I | 75 μM 48 h 72 h | normalized complex I activity | [25] |
c.1294G>C NDUFV1 | complex I | 75 μM 48 h 72 h | OCR and complex I activity significantly ↑ | [25] |
c.1129G>A NDUFV1 | complex I | 75 μM 48 h 72 h | no change | [25] |
c.1142A>G c.11G>A NDUFV1 | complex I | 75 μM 48 h | no change | [43] |
c.1156C>T NDUFV1 | complex I | 75 μM 48 h | basal OCR, ATP production and complex I activity significantly ↑ | [43] |
c.1157G>A NDUFV1 | complex I | 75 μM 48 h 72 h | no change | [25] |
c.54X>A c.207dup NDUFV2 | complex I | 75 μM 48 h | basal OCR significantly ↑ | [43] |
c.120+5_120+8delGTTA NDUFV2 | complex I | 75 μM 48 h 72 h | basal OCR, ATP production and complex I activity significantly ↑ | [43] |
gene deletion NDUFS1 | complex I | 75 μM 48 h 72 h | no change | [25] |
c.683T>C c.755A>C NDUFS1 | complex I | 75 μM 48 h | basal OCR significantly ↑ | [43] |
c.721C>T NDUFS1 | complex I | 75 μM 48 h 72 h | no change | [25] |
c.1139A>T c.63+6T>G NDUFS1 | complex I | 75 μM 48 h | no change | [43] |
c.875T>C c.1328T>A NDUFS2 | complex I | 75 μM 48 h | basal OCR and complex I activity significantly ↑ | [43] |
c.875T>C c.353G>A NDUFS2 | complex I | 75 μM 48 h | no change | [43] |
c.1237T>C NDUFS2 | complex I | 75 μM 48 h | no change | [43] |
c.434C>T NDUFS3 | complex I | 75 μM 48 h 72 h | no change | [25] |
c.291delG NDUFS4 | complex I | 75 μM 48 h | basal OCR, ATP production and complex I activity significantly ↑ | [43] |
c.67del NDUFS6 | complex I | 75 μM 48 h | basal OCR significantly ↑ | [43] |
c.17-1167C>G NDUFS7 | complex I | 75 μM 48 h | no change | [43] |
c.434G>A NDUFS7 | complex I | 75 μM 48 h | basal OCR and complex I activity significantly ↑ | [43] |
unknown | complex I | 75 μM 48 h 72 h | normalized complex I activity | [25] |
unknown | complex I | 25 μM 72 h | no change | [44] |
c.296A>G C8orf38 | complex I | 75 μM 48 h 72 h | no change | [25] |
c.997C>T EFTs | complex I & IV | 25 μM 72 h | ATP production and mitochondrial content significantly ↑ | [44] |
c.509G>A MRPS22 | complex I & IV | 25 μM 72 h | ATP production significantly ↓ ROS significantly ↑ | [44] |
unknown | complex II | 100 μM 48 h | no change | [45] |
c.622G>T NFU1 | complex II | 100 μM 48 h | no change | [45] |
c.1663G>A Fp | complex II | 100 μM 48 h | complex II and CS activity significantly ↑ | [45] |
unknown | complex IV | 100 μM 48 h | no change | [45] |
unknown | complex IV | 100 μM 48 h | complex II and CS activity significantly ↑ | [45] |
unknown | complex IV | 100 μM 48 h | complex II and CS activity significantly ↑ | [45] |
c.312_321del insAT SURF-1 | complex IV | 100 μM 48 h | complex IV and CS activity significantly ↑ | [45] |
c.312_321del insAT SURF-1 | complex IV | 100 μM 48 h | no change | [45] |
c.312_321del insAT SURF-1 | complex IV | 100 μM 48 h | CS activity significantly ↑ | [45] |
c.312_321del10insAT SURF-1 | complex IV | 75 μM 48 h 72 h | no change | [25] |
c.539G>A SURF-1 | complex IV | 75 μM 48 h 72 h | no change | [25] |
c.845_846delCT SURF-1 | complex IV | 100 μM 48 h | no change | [45] |
c.612C>A | complex IV | 75 μM 48 h 72 h | no change | [25] |
c.36142203C>T COX6B1 | complex IV | 25 μM 72 h | mitochondrial content and ROS significantly ↑ | [44] |
c.612C>A COX10 | complex IV | 75 μM 48 h 72 h | complex IV activity significantly ↑ | [25] |
unknown | Complex IV | 25 μM 72 h | no change | [44] |
unknown | complex IV | 100 μM 48 h | complex II and CS activity significantly↑ | [45] |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
De Paepe, B.; Van Coster, R. A Critical Assessment of the Therapeutic Potential of Resveratrol Supplements for Treating Mitochondrial Disorders. Nutrients 2017, 9, 1017. https://doi.org/10.3390/nu9091017
De Paepe B, Van Coster R. A Critical Assessment of the Therapeutic Potential of Resveratrol Supplements for Treating Mitochondrial Disorders. Nutrients. 2017; 9(9):1017. https://doi.org/10.3390/nu9091017
Chicago/Turabian StyleDe Paepe, Boel, and Rudy Van Coster. 2017. "A Critical Assessment of the Therapeutic Potential of Resveratrol Supplements for Treating Mitochondrial Disorders" Nutrients 9, no. 9: 1017. https://doi.org/10.3390/nu9091017